SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ?Sorrento?), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the closing of its previously announced underwritten public offering of 8,333,334 shares of its common stock, Series A warrants to purchase up to an aggregate of 8,333,334 shares of its common stock, Series B warrants to purchase up to an aggregate of 8,333,334 shares of its common stock and Series C warrants to purchase up to an aggregate of 8,333,334 shares of its common stock at a public offering price of $3.00 per share and accompanying warrant combination, before deducting underwriting discounts and commissions and estimated offering expenses payable by Sorrento.? The net proceeds to Sorrento from this offering are expected to be approximately $23.1 million, after deducting underwriting disco
